Preliminary findings from an ongoing assessment show an allogenic leukemia-derived dendritic cell vaccine is capable of generating tumor-specific immune responses as well as potential tumor control in patients with acute myeloid leukemia (AML). The data, presented this weekend at the American Society of Hematology (ASH) 2020 Annual Meeting, also presented 2 incidents in which patients were converted from measurable residual disease (MRD) positive to MRD negative status, with year-plus remission duration, after the vaccination. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more